Topic

Articles

Beyond necessity and nice-to-have, embracing real-world evidence as a true strategic differentiator.

Drug Launch: Winning the Evidence Battle

Michael Christel is Pharmaceutical Executive and Applied Clinical Trials' Managing Editor. He can be reached at mchristel@mmhgroup.com.

Turning to a next-gen psoriasis treatment to help drive future fortunes.

Succession Plan: Skyrizi

While COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.

New Standards for First-to-Launch Players

Uncovering fish oil derivative’s benefit for heart health.

(O)mega Opportunity: Vascepa

Julian Upton is Pharmaceutical Executive’s European and Online Editor. He can be reached at 

New hope accompanies overdue recognition in sickle cell disease fight.

Educational Mission: Oxbryta

Addressing the need for fast-acting therapy in treatment-resistant depression.

First in Class: Spravato

Elaine Quilici is Pharmaceutical Executive's Senior Editor. Email her at equilici@mmh.com

The world’s most expensive drug put in context.

One Time for Lifetime: Zolgensma

How adoption of the key account management (KAM) model can help drive pharma’s agility in reaching and influencing a more diverse set of healthcare customers and decision-makers.

Unlocked Potential — ‘Keying’ in On New-Era Engagement

Staying the Course in Product Launch

Dr. Wolfram Lux is a Senior Director and Dr. Simone Seiter is a Partner in the global Pharma & Biotech practice within Simon-Kucher & Partners Life Sciences Division (Frankfurt, Germany).

Looking at four building blocks of success, Wolfram Lux and Simone Seiter investigate what it takes to win and be successful when commercializing an orphan drug

Strategy